'Raising our largest fund in this environment reflects the consistency of our approach and the work our teams are doing inside our portfolio companies every day,' said Pete Stavros and Nate Taylor, Global Co-Heads of Private Equity at KKR. The strategy is designed to provide a broad range of financing solutions to middle-market companies, spanning private debt, equity, and hybrid capital, while also investing opportunistically in stressed public credit. 'We are grateful to the BXLS VI investors for their strong support of our strategies and the firm's enduring conviction in the life sciences,' said Nicholas Galakatos, Global Head of Blackstone Life Sciences. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
Zippelius will join in September 2026 and will co-lead the strategy alongside Benjamin Breier, with responsibility for originating and executing investments as well as driving value creation across the portfolio. The appointment comes as Partners Group continues to scale its healthcare platform, where it has invested approximately $13.2bn to date across healthcare services, life sciences, and medical technology. 'Pete brings deep sector expertise and a proven track record of building and scaling high-quality healthcare and life sciences businesses,' said Wolf Scheider, Head of Private Equity at Partners Group. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
'We are grateful to the BXLS VI investors for their strong support of our strategies and the firm's enduring conviction in the life sciences,' said Nicholas Galakatos, Global Head of Blackstone Life Sciences. The platform has supported 34 regulatory approvals of medicines and medical devices, including high-profile therapies and technologies, highlighting its role as a strategic capital provider in the sector. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
'We are pleased to support B-FLEXION and management in the creation of a scaled specialty pharmaceutical platform,' said Jonathan Brayman, Managing Director at Blackstone Credit & Insurance. 'This transaction reflects our ability to provide large-scale capital solutions to life sciences companies.' 'We are proud to partner with Blackstone on this next phase of growth for Paratek, as it is a transformative transaction for both the organization and the broader platform,' said Peter Agnes, Operating Partner at B-FLEXION Life Sciences. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
